InPharma also provides specialty guidance utilizing proprietary analytical methodologies, coupled with flow cytometry, to characterize the pharmacokinetics and dynamics of nanoparticles (NPs) and other carrier-mediated agents (CMAs) including drug and antibody-drug conjugates (ADCs).
These technologies are capable of measuring both inactive-encapsulated or conjugated forms in addition to active-released forms of NP/CMAs in a variety of biomatrices, including tissues, and are highly useful in the translational development and characterization of the complex biodisposition of these agents.
These methods may be used to characterize each form of the NP/CMAs as part of formulation development, stability evaluation and in vivo preclinical and clinical PK/PD evaluation.
Other technologies available include novel high throughput screening platforms that profile the uptake and clearance of NP/CMAs in animal and human samples, and novel systems that measure the activity of major clearance pathways in blood to predict NP/CMA PK and PD.
ABOUT US
Dr. Timothy Madden, founder and Director of InPharma has been involved in all aspects of the development of new therapeutic and diagnostic agents for more that 30 years, first academically at institutions such as St. Jude Children’s Research Hospital and M.D. Anderson Cancer Center, and then with multiple pharmaceutical companies.
He’s been responsible for the design, development and conduct of drug development studies associated with more than 150 new agents and devices over the past 30 years.
These include OSI-774, endostatin, bevacizumab, cetuximab, karenitecin, MDAM, 9-aminocamptothecin, bortuzimib, TNP-470, gefitinib, oxaliplatin, bardoxolone methyl, berubicin, Doxil and imatinib.
CONTACT US
Please CONTACT US to learn how we can help in the development of your latest discovery.
Or call,
InPharma was established to aid your therapeutic discovery and development efforts. InPharma’s expertise encompasses a wide range of pharmacology and pharmaceutical science necessary in the development of novel therapeutics. 